Therapeutic Asset Ratings
164 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Navlimetostat
Non-Small Cell Lung Carcinoma
M.D. Anderson Cancer Center
P1/2
CC
(40)
PFL-721
Non-Small Cell Lung Carcinoma
Pierre Fabre Medicament
P1/2
CC
(40)
Selvigaltin
Non-Small Cell Lung Carcinoma
Galecto Biotech AB
P1/2
CC
(40)
Silevertinib
Non-Small Cell Lung Carcinoma
Black Diamond Therapeutics, Inc.
P1/2
CC
(40)
STX-721
Non-Small Cell Lung Carcinoma
Pierre Fabre Medicament
P1/2
CC
(40)
SYS6090
Non-Small Cell Lung Carcinoma
Shanghai JMT-Bio Inc.
P1/2
CC
(40)
Tuvusertib
Non-Small Cell Lung Carcinoma
EMD Serono Research & Development Institute, Inc.
P1/2
CC
(40)
XYA02
Non-Small Cell Lung Carcinoma
XYone Therapeutics, Inc
P1/2
CC
(40)
Migoprotafib
Non-Small Cell Lung Carcinoma
Genentech, Inc.
P1
C
(39)
pf-07257876
Non-Small Cell Lung Carcinoma
Pfizer
P1
C
(39)
177lu-dfc413
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals
P1
C
(36)
[18F]DK222
Non-Small Cell Lung Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1
C
(36)
68Ga-NNS309
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals
P1
C
(36)
Abbv-400
Non-Small Cell Lung Carcinoma
AbbVie
P1
C
(36)
Absk112
Non-Small Cell Lung Carcinoma
Abbisko Therapeutics Co, Ltd
P1
C
(36)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
Non-Small Cell Lung Carcinoma
USWM CT, LLC
P1
C
(36)
Azirkitug
Non-Small Cell Lung Carcinoma
AbbVie
P1
C
(36)
ba1302
Non-Small Cell Lung Carcinoma
Shandong Boan Biotechnology Co., Ltd
P1
C
(36)
Bbo-10203
Non-Small Cell Lung Carcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
P1
C
(36)
Bbo-11818
Non-Small Cell Lung Carcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
P1
C
(36)
bg-60366
Non-Small Cell Lung Carcinoma
BeOne Medicines
P1
C
(36)
bnt316
Non-Small Cell Lung Carcinoma
BioNTech SE
P1
C
(36)
bt02
Non-Small Cell Lung Carcinoma
Biotroy Therapeutics
P1
C
(36)
cgt4255
Non-Small Cell Lung Carcinoma
Cogent Biosciences, Inc.
P1
C
(36)
Chs-006
Non-Small Cell Lung Carcinoma
Coherus Oncology, Inc.
P1
C
(36)
Showing 101 to 125 of 164 assets
Previous
Page 5 of 7
Next